South Korean FDA Approval For Green Cross’ Neulapeg®

Green Cross receives regulatory approval for its once-per-cycle dose neutropenia drug, Neulapeg®.

AsianScientist (Aug. 27, 2014) – Green Cross, a South Korean biopharmaceutical company, has been granted South Korea’s Ministry of Food and Drug Safety authorization for Neulapeg® (pegteograstim), a treatment for abnormally low level of neutrophils in patient undergoing chemotherapy.

Green Cross anticipates that this approval will be an important boost to further support for the company’s efforts to expand its cancer care products.

Neulapeg® is a long-acting PEGylated recombinant human granulocyte-colony stimulating factor (G-CSF), indicated for the reduction of the duration of neutropenia in patients treated to eliminate solid tumour and malignant lymphoma with cytotoxic chemotherapy. The clinical trials showed non-inferiority of the efficacy and tolerability of Neulapeg® to pegfilgrastim.

This new medicine is intended as a fixed once-per-cycle dose, unlike currently marketed first generation G-CSF products which require four to six daily injections following each cycle of chemotherapy.

Neutropenia (a granulocyte disorder characterized by an abnormally low number of neutrophils) is one of the most serious side effects of chemotherapy. Neutropenia can put some patients at risk for severe infections and may cause interruptions in cancer treatment.

“This is a significant milestone for Green Cross as Neulapeg® is the first Green Cross oncology supportive care treatment product.” said Kim Su-Jung, oncology team leader of Green Cross. “Neulapeg® will be available in the Korean market early next year. We are poised to accelerate the introduction of Neulapeg®into foreign markets.”

—–

Source: Green Cross.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.

Asian Scientist Magazine is an award-winning science and technology magazine that highlights R&D news stories from Asia to a global audience. The magazine is published by Singapore-headquartered Wildtype Media Group.

Related Stories from Asian Scientist